Peptides and combination of peptides of non-cancer derivations for use in immunotherapy against different types of cancers
By developing new peptide sequences and combinations derived from human tumor cells, combined with HLA-I class molecules, we solve the problems of high side effects of cancer treatment and difficulty in determining biomarkers in the existing technology, and achieve the goal of treating various cancers such as acute myeloid leukemia. and effective immunotherapy for breast cancer, improving treatment efficiency and diagnostic accuracy.
Patent Information
- Application Number
- CN202011611064.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-03-27
- Filing Date
- 2019-02-08
- Publication Date
- 2021-06-08
AI Technical Summary
Existing cancer immunotherapy has problems such as high side effects, high treatment costs, and difficulty in determining biomarkers when treating different types of cancer. Especially in diseases such as AML, breast cancer, and cholangiocarcinoma, there is a lack of effective targeted therapy. plan.
A series of novel peptide sequences and peptide combinations, derived from HLA class I molecules of human tumor cells, have been developed for use in vaccine compositions to elicit anti-tumor immune responses or as immunologically active compounds that bind to MHC molecules to activate T cells against specific Cancers such as acute myeloid leukemia, breast cancer, cholangiocarcinoma, etc. are treated.
Through these peptide sequences and combinations, we can effectively stimulate anti-tumor immune responses, reduce side effects, improve treatment efficiency, and provide potential biomarkers for diagnosis and prediction of treatment success rate, suitable for many types of cancer, including acute myeloid Leukemia, breast cancer, cholangiocarcinoma, etc.